Ionis Advances Alzheimer’s Research as Biogen’s Diranersen Shows Historic Reduction in Tau Pathology
First Phase 2 Study Demonstrates Measurable Reductions in Tau and Cognitive Gains for Early Alzheimer’s
Investors and the scientific community received a significant update from Ionis and its partner Biogen today. Topline results from the Phase 2 CELIA study indicate diranersen (BIIB080)—a therapy developed to target the tau protein—achieved a first in Alzheimer’s research: robust reductions in tau pathology alongside cognitive benefits for patients with early-stage disease.
Biomarker and Cognitive Data Support Next-Stage Development
Diranersen’s performance in CELIA showed that while the primary endpoint—a dose-response change on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 76—was not met, the therapy made a noteworthy mark. Biomarker results demonstrated significant reductions in both cerebrospinal fluid (CSF) tau and tau pathology across all dosages, mirroring findings from earlier Phase 1b trials. Furthermore, exploratory analyses revealed a slowing in clinical decline, most pronounced at the lowest dose (60 mg every 24 weeks), pointing to a real-world benefit for early Alzheimer’s patients.
Safety Profile In Line With Expectations and Prior Trials
Importantly for future regulatory milestones, diranersen’s safety and tolerability outcomes were consistent with earlier studies, with no new adverse signals. The frequency of adverse events remained similar across dose groups, though the highest dose group experienced a greater incidence of serious adverse events. This safety record supports moving forward with registrational development.
Key CELIA Study Findings at a Glance
| Study Attribute | Key Finding |
|---|---|
| Disease Focus | Early Alzheimer’s Disease |
| Participants | 416 (no prior anti-amyloid therapy) |
| Dosing Arms | 60 mg/24wks 115 mg/24wks 115 mg/12wks |
| Primary Endpoint | Dose response on CDR-SB at Week 76 (not met) |
| Tau Pathology | Robust reduction across all doses |
| Cognitive Benefit | Slowing of clinical decline, especially at lowest dose |
| Safety | Consistent with prior trials |
| Next Steps | Advance to registrational development; data presentations planned for AAIC 2026 |
What’s Next: Registrational Trials and Ongoing Research
Biogen, citing the compelling blend of biomarker and efficacy data, plans to push diranersen to registrational development. Longer-term studies are underway to assess sustained safety and durability of effect, with further details to be shared at major scientific congresses, including the Alzheimer’s Association International Conference in 2026.
Takeaway: A Step Forward in Alzheimer’s, But With Open Questions
While CELIA’s primary endpoint was not achieved, the consistency and magnitude of secondary results represent a leap forward for tau-targeting Alzheimer’s therapies. With the FDA having granted Fast Track designation and safety findings in line with expectations, investors and those following Alzheimer’s innovations should keep close watch as diranersen enters its next development phase. The big question now: will this therapy’s biomarker and cognitive gains translate into a clinically meaningful, approved treatment for patients in need?
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI